ASSESSMENT OF EFFECT OF SHODHANA ON PHYTOCHEMICAL AND CHROMATOGRAPHICAL PROFILE OF DIFFERENT LEVELS OF CLASSICAL PROCESSED DANTI (BALIOSPERMUM MONTANUM WILLD.) ROOT

Objective: Ayurveda recommends the use of Danti root after Shodhana (Processing/Purification) where the powder Pippali (Piperlongum Linn.) fruit, honey and Kusha (Desmostachya bippinata Stapf.) leaves are being used. But the additive effect of all these drugs on Danti root are yet to be explored scientifically. Principal component analysis (PCA), a multivariate data analysis technique targeting to assess the discrimination effect of psychic nut, for evaluating the additive effect, can be used to assess the effect of Shodhana on preliminary physicochemical, phytochemical parameters upon four levels of Danti (Baliospermum montanum Willd.) root.Methods: Roots of raw Danti, after proper botanical authentication, were subjected for classically recommended Shodhana procedure and four groups of Danti root like raw Danti (RD), Classical processed Danti root (CPDR), Kusha processed Danti root (KPDR), water processed Danti root (WPDR) were obtained at various levels of Danti Shodhana. Methanolic macerated extracts of all four Danti root groups were subjected for preliminary physicochemical, phytochemical and chromatographic screening. The obtained data were analyzed with the help of the Un-scrambler Camo Software for multivariate data analysis.Results: The methanolic and water extractive value of CPDR group is more than remaining sections holding lower ash value and high-intensity colour reaction during phytochemical screenings of steroid, flavonoid etc.Conclusion: Analysis of PCA technique suggests a similar trend in between RD and KPDR group while CPDR and WPDR on a different in score plot

Unbiased Characterization of Anopheles Mosquito Blood Meals by Targeted High-Throughput Sequencing

Understanding mosquito host choice is important for assessing vector competence or identifying disease reservoirs. Unfortunately, the availability of an unbiased method for comprehensively evaluating the composition of insect blood meals is very limited, as most current molecular assays only test for the presence of a few pre-selected species. These approaches also have limited ability to identify the presence of multiple mammalian hosts in a single blood meal. Here, we describe a novel high-throughput sequencing method that enables analysis of 96 mosquitoes simultaneously and provides a comprehensive and quantitative perspective on the composition of each blood meal. We validated in silico that universal primers targeting the mammalian mitochondrial 16S ribosomal RNA genes (16S rRNA) should amplify more than 95% of the mammalian 16S rRNA sequences present in the NCBI nucleotide database. We applied this method to 442 female Anopheles punctulatus s. l. mosquitoes collected in Papua New Guinea (PNG). While human (52.9%), dog (15.8%) and pig (29.2%) were the most common hosts identified in our study, we also detected DNA from mice, one marsupial species and two bat species. Our analyses also revealed that 16.3% of the mosquitoes fed on more than one host. Analysis of the human mitochondrial hypervariable region I in 102 human blood meals showed that 5 (4.9%) of the mosquitoes unambiguously fed on more than one person. Overall, analysis of PNG mosquitoes illustrates the potential of this approach to identify unsuspected hosts and characterize mixed blood meals, and shows how this approach can be adapted to evaluate inter-individual variations among human blood meals. Furthermore, this approach can be applied to any disease-transmitting arthropod and can be easily customized to investigate non-mammalian host sources

Probing R-parity violating models of neutrino mass at the Tevatron via top Squark decays

We have estimated the limiting branching ratio of the R-parity violating (RPV) decay of the lighter top squark, \tilde t_1 \ar l^+ d ($l=e$ or $\mu$ and d is a down type quark of any flavor), as a function of top squark mass(\MST) for an observable signal in the di-lepton plus di-jet channel at the Tevatron RUN-II experiment with 2 fb$^{-1}$ luminosity. Our simulations indicate that the lepton number violating nature of the underlying decay dynamics can be confirmed via the reconstruction of \MST. The above decay is interesting in the context of RPV models of neutrino mass where the RPV couplings ($\lambda'_{i3j}$) driving the above decay are constrained to be small (\lsim 10^{-3} - 10^{-4} ). If $\tilde t_1$ is the next lightest super particle - a theoretically well motivated scenario - then the RPV decay can naturally compete with the R-parity conserving (RPC) modes which also have suppressed widths. The model independent limiting BR can delineate the parameter space in specific supersymmetric models, where the dominating RPV decay is observable and predict the minimum magnitude of the RPV coupling that will be sensitive to Run-II data. We have found it to be in the same ballpark value required by models of neutrino mass, for a wide range of \MST. A comprehensive future strategy for linking top squark decays with models of neutrino mass is sketched.Comment: 28 pages, 14 Figure

Summary of the Activities of the Working Group I on High Energy and Collider Physics

This is a summary of the projects undertaken by the Working Group I on High Energy Collider Physics at the Eighth Workshop on High Energy Physics Phenomenology (WHEPP8) held at the Indian Institute of Technology, Mumbai, January 5-16, 2004. The topics covered are (i) Higgs searches (ii) supersymmetry searches (iii) extra dimensions and (iv) linear collider.Comment: summary of Working Group I at the Eighth Workshop on High Energy Physics Phenomenology (WHEPP8), I.I.T., Mumbai, January 5-16, 200

Point-of-care testing and treatment of sexually transmitted infections to improve birth outcomes in high-burden, low-income settings: Study protocol for a cluster randomized crossover trial (the WANTAIM Trial, Papua New Guinea) [version 1; peer review: 1 approved, 1 approved with reservations]

Background: Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis and bacterial vaginosis have been associated with preterm birth and low birth weight, and are highly prevalent among pregnant women in many low- and middle-income settings. There is conflicting evidence on the potential benefits of screening and treating these infections in pregnancy. Newly available diagnostic technologies make it possible, for the first time, to conduct definitive field trials to fill this knowledge gap. The primary aim of this study is to evaluate whether antenatal point-of-care testing and immediate treatment of these curable sexually transmitted and genital infections (STIs) leads to reduction in preterm birth and low birth weight. Methods : The Women and Newborn Trial of Antenatal Interventions and Management (WANTAIM) is a cluster-randomised crossover trial in Papua New Guinea to compare point-of-care STI testing and immediate treatment with standard antenatal care (which includes the WHO-endorsed STI ‘syndromic’ management strategy based on clinical features alone without laboratory confirmation). The unit of randomisation is a primary health care facility and its catchment communities. The primary outcome is a composite measure of two events: the proportion of women and their newborns in each trial arm, who experience either preterm birth (delivery <37 completed weeks of gestation as determined by ultrasound) and/or low birth weight (<2500 g measured within 72 hours of birth). The trial will also evaluate neonatal outcomes, as well as the cost-effectiveness, acceptability and health system requirements of this strategy, compared with standard care. Conclusions: WANTAIM is the first randomised trial to evaluate the effectiveness, cost-effectiveness, acceptability and health system requirements of point-of-care STI testing and treatment to improve birth outcomes in high-burden settings. If the intervention is proven to have an impact, the trial will hasten access to these technologies and could improve maternal and neonatal health in high-burden settings worldwide. Registration: ISRCTN37134032

Point-of-care testing and treatment of sexually transmitted and genital infections during pregnancy in Papua New Guinea (WANTAIM trial): protocol for an economic evaluation alongside a cluster-randomised trial

INTRODUCTION: Left untreated, sexually transmitted and genital infections (henceforth STIs) in pregnancy can lead to serious adverse outcomes for mother and child. Papua New Guinea (PNG) has among the highest prevalence of curable STIs including syphilis, chlamydia, gonorrhoea, trichomoniasis and bacterial vaginosis, and high neonatal mortality rates. Diagnosis and treatment of these STIs in PNG rely on syndromic management. Advances in STI diagnostics through point-of-care (PoC) testing using GeneXpert technology hold promise for resource-constrained countries such as PNG. This paper describes the planned economic evaluation of a cluster-randomised cross-over trial comparing antenatal PoC testing and immediate treatment of curable STIs with standard antenatal care in two provinces in PNG. METHODS AND ANALYSIS: Cost-effectiveness of the PoC intervention compared with standard antenatal care will be assessed prospectively over the trial period (2017-2021) from societal and provider perspectives. Incremental cost-effectiveness ratios will be calculated for the primary health outcome, a composite measure of the proportion of either preterm birth and/or low birth weight; for life years saved; for disability-adjusted life years averted; and for non-health benefits (financial risk protection and improved health equity). Scenario analyses will be conducted to identify scale-up options, and budget impact analysis will be undertaken to understand short-term financial impacts of intervention adoption on the national budget. Deterministic and probabilistic sensitivity analysis will be conducted to account for uncertainty in key model inputs. ETHICS AND DISSEMINATION: This study has ethical approval from the Institutional Review Board of the PNG Institute of Medical Research; the Medical Research Advisory Committee of the PNG National Department of Health; the Human Research Ethics Committee of the University of New South Wales; and the Research Ethics Committee of the London School of Hygiene and Tropical Medicine. Findings will be disseminated through national stakeholder meetings, conferences, peer-reviewed publications and policy briefs. TRIAL REGISTRATION NUMBER: ISRCTN37134032